Not sure if the purchase of Acerta has been discussed here.

AstraZeneca purchased 55% of Acerta Pharma BV for $4 billion...$2.5 billion up front and $1.5 billion $1.5 billion when acalabrutinib is approaved by a regulator or 2018, whichever comes first. The deal also includes conditions which would allow AZ to buy the rest of the company for an additional $3 billion. I'm not sure if acalabrutinib is a block buster cancer drug.

From what I have read Acerta has promising drug development processes...as do Resverlogix and Zenith.

So if I have calculated correctly a deal like this RVX would yield $25/share at signing and another $15/share when BoM completes in late 2018 for apabetalone and then if an aquirer bought the company (RVX) it would yield another $30/share...not bad - $70/share in total.

I remember posters talking about CVR type deals with RVX a few years ago but we haven't seen any action yet but it is still possible and BETonMACE is well underway.

I'd be interested in perspectives re this AZ / Ascerta deal.

Cheers

Toinv